Phase I Study of Lonafarnib (SCH66336) and Gleevec (Imatinib Mesylate) in Chronic Myelogenous Leukemia (CML).

Trial Profile

Phase I Study of Lonafarnib (SCH66336) and Gleevec (Imatinib Mesylate) in Chronic Myelogenous Leukemia (CML).

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2012

At a glance

  • Drugs Imatinib (Primary) ; Lonafarnib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Feb 2012 Additional lead trial investigator (Cortes JE) and actual patient no (23) identified as reported by ClinicalTrials.gov.
    • 31 Oct 2006 Status change
    • 06 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top